Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Cancer Discov. 2020 Jan 8;10(3):440–459. doi: 10.1158/2159-8290.CD-19-0116

Figure 3: BRD3308 is effective in primary DLBCL.

Figure 3:

A) The sensitivity of primary DLBCL tumors to BRD3308 was evaluated by expanding them in vivo, followed by culture in our in vitro organoid model with different concentrations of BRD3308. A dose-dependent decrease in cell viability was observed in all 6 tumors with increasing concentrations of BRD3308. B) Treatment of 3 unique DLBCL xenograft models in vivo with 25mg/kg (green) or 50mg/kg (orange) of BRD3308 significantly reduced tumor growth compared to vehicle (black) (**P<0.01; ***P<0.001). C) Representative MRI images of renal capsule implanted PDX tumors from a CREBBPR1446C mutant DLBCL at the beginning (day 0) and day 14 of treatment. Tumor is outlined in yellow. D) Quantification of tumor volume by MRI images, normalized to the pre-treatment volume for the same tumor, shows that BRD3308 treatment significantly reduces tumor growth (*P<0.05, **P<0.01).